Health-related quality of life of chronic liver disease patients with and without hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 2, 2007, Pages 197-203

  Kondo, Yuji ^a   Yoshida, Haruhiko ^a   Tateishi, Ryosuke ^a   Shiina, Shuichiro ^a   Mine, Norio ^a   Yamashiki, Noriyo ^a   Sato, Shinpei ^a   Kato, Naoya ^a   Kanai, Fumihiko ^a   Yanase, Mikio ^a   Yoshida, Hideo ^a   Akamatsu, Masatoshi ^a   Teratani, Takuma ^a   Kawabe, Takao ^a   Omata, Masao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Chronic liver disease; Health related quality of life; Hepatocellular carcinoma; Percutaneous tumor ablation therapy

Indexed keywords

ALBUMIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER THERAPY; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; JAPANESE; LABORATORY TEST; LIVER CELL CARCINOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PERCUTANEOUS ABLATION THERAPY; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SHORT FORM 36;

EID: 33846639568     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04456.x     Document Type: Article

References (37)

1. Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N. Engl. J. Med. 1996; 334: 835-40.
2. Marchesini G, Bianchi G, Amodio P et al. Factors associated with poor health-related quality of life of patients with cirrhosis. Gastroenterology 2001; 120: 170-8.
3. Poupon RE, Chretien Y, Chazouilleres O, Poupon R, Chwalow J and the French-PBC Study Group. Quality of life in patients with primary biliary cirrhosis. Hepatology 2004; 40: 489-94.
4. Younossi ZM, Guyatt G. Quality-of life assessments and chronic liver disease. Am. J. Gastroenterol. 1998; 93: 1037-41.
5. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27: 209-12.
6. Bonkovsky HL, Woolley JM and the Consensus Interferon Study Group. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 1999; 29: 264-70.
7. Cordoba J, Flavia M, Jacas C et al. Quality of life and cognitive function in hepatitis C at different stages of liver disease. J. Hepatol. 2003; 39: 231-8.
8. Spiegel BMR, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health-related quality of life: a systematic review and quantitative assessment. Hepatology 2005; 41: 790-800.
9. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: An update. Ann. Intern. Med. 2003; 139: 817-23.
10. Kiyosawa K, Umemura T, Ichijo T et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004; 127: S17-S26.
11. Bianchi G, Loguercio C, Sgarbi D et al. Reduced quality of life of patients with hepatocellular carcinoma. Dig. Liver Dis. 2003; 35: 46-54.
12. Poon RTP, Fan ST, Yu WC, Lam BKY, Chan FYS, Wong J. A prospective longitudinal study of quality of life after resection of hepatocellular carcinoma. Arch. Surg. 2001; 136: 693-9.
13. Tanabe G, Ueno S, Maemura M et al. Favorable quality of life after repeat hepatic resection for recurrent hepatocellular carcinoma. Hepatogastroenterology 2001; 48: 506-10.
14. Shiratori Y, Yoshida H, Omata M. Management of hepatocellular carcinoma: advances in diagnosis, treatment and prevention. Expert Rev. Anticancer Ther. 2001; 1: 277-90.
15. Omata M, Tateishi R, Yoshida H, Shiina S. Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: ethanol injection therapy and radiofrequency ablation. Gastroenterology 2004; 127: S159-66.
16. Shiina S, Teratani T, Obi S et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129: 122-30.
17. Tateishi R, Shiina S, Teratani T et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma: An analysis of 1000 cases. Cancer 2005; 103: 1201-9.
18. Livraghi T, Giorgio A, Marin G et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long term results of percutaneous ethanol injection. Radiology 1995; 197: 101-8.
19. Shiina S, Tagawa K, Niwa Y et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients. AJR Am. J. Roentgenol. 1993; 160: 1023-8.
20. Rossi S, Di Stasi M, Buscarini E et al. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. AJR Am. J. Roentgenol. 1996; 167: 759-68.
21. Livrhagi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999; 210: 655-61.
22. Ikeda K, Saitoh S, Tsubota A et al. Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. Cancer 1993; 71: 19-25.
23. Koike Y, Shiratori Y, Sato S et al. Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus: an analysis of 236 consecutive patients with a single lesion. Hepatology 2000; 32: 1216-23.
24. Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K. Translation, adaptation, and validation of the SF-36 health survey for use in Japan. J. Clin. Epidemiol. 1998; 51: 1037-44.
25. Fukuhara S, Ware JE, Kosinski M, Wada S, Gandek B. Psychometric and clinical tests of validity of the Japanese SF-36 health survey. J. Clin. Epidemiol. 1998; 51: 1045-53.
26. Thein HH, Krahn M, Kaldor JM, Dore GJ. Estimation of utilities for chronic hepatitis C from SF-36 scores. Am. J. Gastroenterol. 2005; 100: 643-51.
27. Younossi ZM, Boparai N, McCormick RN, Price LL, Guyatt G. Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am. J. Gastroenterol. 2001; 96: 579-83.
28. Nichol MB, Sengupta N, Globe DR. Evaluating quality-adjusted life years: estimation of the health utility index (HUI2) from the SF-36. Med. Decis. Making 2001; 21: 105-12.
29. Fryback DG, Lawewncw WF, Martin PA, Klein R, Klein BE. Predicting quality of well-being scores from the SF-36: results from the Beaver Dam Health Outcome Study. Med. Decis. Making 1997; 17: 1-9.
30. Fukuhara S, Suzugamo Y. SF-36 v2 Japanese Manual. Kyoto: Hope International, 2004. Available from: http://www.sf-36.jp
31. Liaw YF, Sung JJY, Chow WC et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004; 351: 1521-31.
32. Hui JM, George J, Liddle C et al. Changes in serum albumin during treatment of chronic hepatitis B with lamivudine: effects of response and emergence of drug resistance. Am. J. Gastroenterol. 2002; 97: 1003-9.
33. Shiratori Y, Imazeki F, Moriyama M et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann. Intern. Med. 2000; 132: 517-24.
34. Yoshida H, Shiratori Y, Moriyama M et al. Interferon therapy reduces the risk for hepatocellular carcinoma. National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann. Intern. Med. 1999; 131: 174-81.
35. Shiratori Y, Shiina S, Teratani T et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann. Intern. Med. 2003; 138: 299-306.
36. Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease-specific questionnaire to measure health-related quality of life in patients with chronic liver disease. Gut 1999; 45: 295-300.
37. Gralnek IM, Hays RD, Kilbourne A et al. Development and evaluation of the liver disease quality of life instrument in persons with advanced, chronic liver disease: the LDQOL 1.0. Am. J. Gastroenterol. 2000; 95: 3552-65.